Introduction
Daytrana, with the NDC code 68968-5554, is a transdermal patch containing methylphenidate, a central nervous system stimulant. It is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients aged 6 to 17 years. Here, we will delve into the market analysis and price projections for this medication.
Market Overview
Indications and Usage
Daytrana is specifically designed for the treatment of ADHD in pediatric patients. Its unique transdermal delivery system provides a convenient and consistent release of methylphenidate over a 9-hour period, which can be beneficial for patients who have difficulty with oral medications[4].
Market Demand
The demand for ADHD medications, including Daytrana, is significant due to the prevalence of ADHD among children and adolescents. According to various studies, ADHD affects a substantial portion of the pediatric population, ensuring a steady market demand for effective treatments.
Pricing Dynamics
Current Pricing
As of the latest data, Daytrana is classified as a Human Prescription Drug and is distributed by Noven Therapeutics, LLC. The active ingredient strength is 20 mg/9h, and it is a DEA Schedule CII drug, indicating a high potential for abuse and misuse[1][4].
Historical Price Trends
While specific historical price data for Daytrana is not provided, the broader context of prescription drug pricing in the U.S. is relevant. Many prescription drugs, including those for chronic conditions like ADHD, have seen significant price increases over the years. For example, a report by the Office of the Assistant Secretary for Planning and Evaluation (ASPE) noted that many prescription drugs have had list price increases ranging from 20% to 55% between 2018 and 2023[2].
International Price Comparisons
U.S. prices for prescription drugs, including brand-name medications like Daytrana, are generally higher than those in other high-income countries. A study comparing U.S. prices to those in 33 OECD countries found that U.S. prices were nearly three times as high as prices in these countries[3].
Regulatory and Policy Impacts
Medicare Drug Price Negotiation Program
Although Daytrana is not listed among the initial 10 drugs selected for the Medicare Drug Price Negotiation Program, the program's impact on the broader pharmaceutical market is noteworthy. The program has resulted in significant discounts for selected drugs, ranging from 38% to 79% off the list prices. This could set a precedent for future negotiations and potentially influence pricing strategies across the industry[2][5].
Price Projections
Short-Term Projections
Given the current pricing trends and the lack of specific data indicating a price reduction for Daytrana, it is likely that the price will remain stable or increase slightly in the short term. However, any changes in regulatory policies or market dynamics could impact this projection.
Long-Term Projections
In the long term, several factors could influence the pricing of Daytrana:
- Regulatory Changes: Future expansions of the Medicare Drug Price Negotiation Program or other regulatory initiatives aimed at reducing prescription drug costs could lead to lower prices.
- Market Competition: The introduction of generic or biosimilar versions of methylphenidate could increase competition and drive prices down.
- Economic Factors: Economic conditions, such as inflation or changes in healthcare spending, can also impact drug pricing.
Key Takeaways
- Market Demand: The demand for ADHD treatments like Daytrana is steady due to the prevalence of ADHD.
- Pricing Trends: U.S. prescription drug prices, including those for ADHD medications, have historically been high and subject to significant increases.
- Regulatory Impact: Programs like the Medicare Drug Price Negotiation Program could influence future pricing strategies.
- International Comparisons: U.S. prices for prescription drugs are generally higher than those in other countries.
FAQs
What is Daytrana used for?
Daytrana is a transdermal patch used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients aged 6 to 17 years[4].
Who distributes Daytrana?
Daytrana is distributed by Noven Therapeutics, LLC[1].
What is the DEA schedule for Daytrana?
Daytrana is classified as a DEA Schedule CII drug, indicating a high potential for abuse and misuse[1][4].
How does Daytrana compare in price to other countries?
U.S. prices for prescription drugs, including Daytrana, are generally higher than those in other high-income countries[3].
Are there any regulatory initiatives that could affect Daytrana's price?
Yes, initiatives like the Medicare Drug Price Negotiation Program could set a precedent for future price negotiations and potentially influence the pricing of Daytrana and other prescription drugs[2][5].
Sources
- FDA Report: NDC 68968-5554 Transdermal Patch Daytrana Drug - FDA.report
- ASPE Brief: Medicare Drug Price Negotiation Program - ASPE - HHS.gov
- ASPE Report: International Prescription Drug Price Comparisons: Estimates Using IQVIA MIDAS Data - ASPE - HHS.gov
- DailyMed Label: DAYTRANA- methylphenidate patch - DailyMed
- CMS Fact Sheet: Medicare Drug Price Negotiation Program - CMS
